- Omeros Corporation, based in Seattle, has submitted a Biologics License Application (BLA) to the FDA seeking approval for its drug candidate, narsoplimab.
- Omeros Corporation's drug received FDA approval and is currently undergoing review by the European Medicines Agency.
The FDA and European Medicines Agency engaged in joint coordination regarding regulatory dossier evaluation.
1 report, 1 independent
Updated Jun 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA and European Medicines Agency engaged in joint coordination regarding regulatory dossier evaluation.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Hospitals in India, Israel, and the Netherlands are currently experimenting with dose reduction protocols for clinical trials under the purview of the FDA and the European Medicines Agency.Sub-event
FDA and EMA coordinated on regulatory dossier evaluation.1 source
Keep exploring
The entities involved
- FDA
-
European Medicines Agency
highest regulatory authority on medicines in the European Union
Related events
- Both the FDA and the European Medicines Agency govern drug approval processes.
- The FDA and European Medicines Agency are harmonizing regulatory review of drug applications.
- The FDA is reviewing drug data and company resubmissions, while also overseeing the functions of the U.S. Department of Health and Human Services.
- FDA reviewed protocol amendment and interim safety data for a company's product.
- The FDA and European Medicines Agency discussed sharing the global regulatory leadership mantle.